Myelofibrosis screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(Mahshid) |
||
Line 19: | Line 19: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] |
Revision as of 02:51, 27 November 2017
Myelofibrosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Myelofibrosis screening On the Web |
American Roentgen Ray Society Images of Myelofibrosis screening |
Risk calculators and risk factors for Myelofibrosis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
There is insufficient evidence to recommend routine screening for myelofibrosis.[1]
Screening
There is insufficient evidence to recommend routine screening for myelofibrosis.[1]
References
- ↑ 1.0 1.1 Screening of myelofibrosis. U.S. preventive services task force 2016. http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=myelofibrosis. Accessed on March 10, 2016